Form 8-K - Current report:
SEC Accession No. 0000950170-21-004087
Filing Date
2021-11-10
Accepted
2021-11-10 16:15:53
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20211110.htm   iXBRL 8-K 59284
2 EX-99.1 clsd-ex99_1.htm EX-99.1 180153
3 GRAPHIC img171462827_0.jpg GRAPHIC 6360
  Complete submission text file 0000950170-21-004087.txt   381603

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20211110_pre.xml EX-101.PRE 10230
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20211110_lab.xml EX-101.LAB 13896
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20211110.xsd EX-101.SCH 2487
7 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20211110_htm.xml XML 4894
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 211396820
SIC: 2834 Pharmaceutical Preparations